52,279 Shares in BioNTech SE Sponsored ADR $BNTX Bought by Hsbc Holdings PLC

Key Points

• HSBC Holdings PLC opened a new position in BioNTech, buying 52,279 shares worth about $4.97 million in the fourth quarter.
• Other institutions also adjusted their holdings, while institutional investors now own 15.52% of BioNTech’s stock. Notable activity included Royal Bank of Canada, Russell Investments, and DZ BANK increasing positions.
• BioNTech announced a $1 billion share repurchase program, signaling management may see the stock as undervalued. Meanwhile, analysts have a consensus rating of Moderate Buy with an average price target of $129.56.

Hsbc Holdings PLC bought a new position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 52,279 shares of the company's stock, valued at approximately $4,969,000.

Other institutional investors have also recently made changes to their positions in the company. Royal Bank of Canada raised its position in shares of BioNTech by 95.9% during the first quarter. Royal Bank of Canada now owns 7,177 shares of the company's stock worth $653,000 after acquiring an additional 3,514 shares during the last quarter. NewEdge Advisors LLC bought a new stake in BioNTech in the first quarter valued at approximately $167,000. Russell Investments Group Ltd. boosted its holdings in BioNTech by 368,800.0% in the second quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company's stock valued at $1,178,000 after acquiring an additional 11,064 shares during the last quarter. Natixis acquired a new stake in BioNTech during the 2nd quarter valued at approximately $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in BioNTech by 2.9% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company's stock valued at $52,416,000 after purchasing an additional 13,788 shares during the period. Institutional investors own 15.52% of the company's stock.

Insider Transactions at BioNTech

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the firm's stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the sale, the chief operating officer directly owned 399,387 shares in the company, valued at approximately $44,156,226.72. This trade represents a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

BNTX has been the topic of a number of recent analyst reports. Berenberg Bank dropped their price target on shares of BioNTech from $155.00 to $140.00 and set a "buy" rating on the stock in a research report on Tuesday, May 12th. The Goldman Sachs Group reiterated a "buy" rating on shares of BioNTech in a research report on Wednesday, March 11th. Truist Financial raised shares of BioNTech to a "strong-buy" rating in a research note on Wednesday, March 25th. Weiss Ratings restated a "sell (d-)" rating on shares of BioNTech in a report on Wednesday, April 8th. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of BioNTech in a research report on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $129.56.

BioNTech Price Performance

Shares of BNTX opened at $91.22 on Friday. The firm has a market cap of $23.07 billion, a PE ratio of -15.51 and a beta of 1.32. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00. The business's 50 day moving average price is $93.96 and its two-hundred day moving average price is $97.92. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.74 and a current ratio of 8.80.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The company had revenue of $1.06 billion for the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%. On average, equities analysts anticipate that BioNTech SE Sponsored ADR will post -5.67 EPS for the current year.

BioNTech declared that its Board of Directors has authorized a stock repurchase plan on Thursday, May 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 4.2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its shares are undervalued.

BioNTech Company Profile

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.